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ABSTRACT: Over eight different families of natural products
consisting of nearly 70 secondary metabolites that contain
the bicyclo[2.2.2]diazaoctane ring system have been isolated
from various Aspergillus, Penicillium, and Malbranchea species.
Since 1968, these secondary metabolites have been the focus
of numerous biogenetic, synthetic, taxonomic, and biological
studies and, as such, have made a lasting impact across
multiple scientific disciplines. This review covers the isolation,
biosynthesis, and biological activity of these unique secondary
metabolites containing the bridging bicyclo[2.2.2]diazaoctane
ring system. Furthermore, the diverse fungal origin of these natural products is closely examined and, in many cases, updated to
reflect the currently accepted fungal taxonomy.
■ INTRODUCTION
Natural products derived from fungal sources have been an area
of intense research for decades due to the vast structural
diversity and biological activity of these secondary metabolites.
Numerous fungal-derived natural products serve as clinical
therapeutics for both human and animal diseases, and thus the
search for new classes of bioactive secondary metabolites from
terrestrial and marine fungal sources has garnered additional
interest.1 Natural products containing a unique bicyclo[2.2.2]-
diazaoctane ring system are part of a diverse class of biologically
active prenylated indole alkaloids isolated mainly from various
Penicillium and Aspergillus species of fungi.2 The breviana-
mides,3 paraherquamides,4 stephacidins,5 notoamides,6 asper-
paralines,7 marcfortines,8 chrysogenamides,9 and malbranchea-
mides10 exhibit a range of interesting structural features, such
as a bicyclo[2.2.2]diazaoctane nucleus and a complex, oxidized
amino acid skeleton (Figure 1). Structurally, these natural
products are comprised of tryptophan, a cyclic amino acid
(proline, pipecolic acid, or derivatives of proline or pipecolic
acid), and one or two isoprene units. In addition to their
structural diversity, a variety of bioactivities are also present for
these compounds, including but not limited to insecticidal,
cytotoxic, anthelmintic, and antibacterial properties.
Initial characterization of these types of natural products led
to the conclusion that two isoprene units are present in these
alkaloid families, in which one of the two isoprene units is
involved in the formation of the bicyclo[2.2.2]diazaoctane
ring system.11 In order to determine the biosynthetic pathway
from which the isoprene units originate, [13C2]-acetate has been
utilized in precursor incorporation studies with fungal cultures
known to produce metabolites containing the bridging bicycle.
Specific incorporation of intact C2 units, combined with the
13C
coupling patterns observed by 13CNMR spectroscopy, demon-
strated that the isoprene units found in these metabolites arise
from dimethylallyl pyrophosphate (DMAPP), a product of the
mevalonic acid pathway (Scheme 1).11,12
Of the natural products containing the unusual bridging
bicycle, two distinct stereochemical configurations have been
noted with respect to the relative configuration at the C-19
position (brevianamide numbering). The rare anti-configuration
(1) and the more common syn-configuration (2) are determined
by the position of the C−H proton at the bridgehead of
the bicyclic core in relation to the bridging secondary lactam
(Figure 2).13 The brevianamides are currently the only family
of secondary metabolites to display the anti-configuration about
the bridging bicycle; however, it was recently discovered that
two novel metabolites chrysogenamide A and versicolamide B
also display the rare anti-stereochemistry.6f,9 Contrary to this, all
other known metabolites containing the core bridging bicycle
display the syn-configuration.
Since the first isolation of these bicyclo[2.2.2]diazaoctane-
containing metabolites, substantial effort has focused on both
the synthetic and the biosynthetic aspects of this unique
ring system.14,15 However, although relatively little is known
about the microbial assembly and modification of metabolites
containing this core bridging bicycle, new genomic and bio-
chemical approaches are beginning to clarify important aspects
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of these pathways. Originally proposed by Porter and Sammes
in 1970, the biosynthetic formation of the bicyclo[2.2.2]-
diazaoctane ring system is believed to arise via an intra-
molecular hetero Diels−Alder reaction (IMDA) of a 5-hydro-
xypyrazine-2(1H)-one (Scheme 2).16 Extensive synthetic
research carried out by Williams and co-workers has aimed at
supporting a biosynthetic Diels−Alder reaction via the
biomimetic syntheses of several advanced metabolites.15−17
Concurrently, substantial effort has been put forth to isolate
and characterize the putative Diels−Alderase enzyme respon-
sible for this biosynthetic transformation, but, to date, no such
enzyme has been isolated.
The Penicillium and Aspergillus fungal producers of secondary
metabolites containing the bicyclo[2.2.2]diazaoctane ring have
been defined taxonomically based on early phenotypic methods
Figure 1. Structures of several secondary metabolites that contain the core bicyclo[2.2.2]diazaoctane ring system.
Scheme 1. Classical Mevalonic Acid Pathway Showing the Labeling Pattern via 1,2-Doubly Labeled Acetatea
aNote the change in carbon numbering.
Figure 2. Anti- and syn-relationship of the bicyclo[2.2.2]diazaoctane
core.
Scheme 2. Proposed Biosynthetic Diels−Alder Reaction16
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of Raper and Thom18 for Penicillium and Raper and Fennell19
for Aspergillus. However, several of these species have since
been reclassified based on modern molecular methods.
Extensive taxonomical research carried out by Frisvad and
co-workers has provided new phylogenetic information for each
fungal culture known to produce the bicyclo[2.2.2]diazaoctane
ring system described in this review, and both the original and
updated fungal strain nomenclature will be mentioned when
applicable. Furthermore, numerous strains of these fungal
cultures have been determined to produce the same sets of
secondary metabolites (Table 1). Taxonomic revisions of
species and reidentifications of the strains are based on a
polyphasic approach, including morphological, physiological,
chemical, and DNA sequence data. Mostly sequences from
β-tubulin and calmodulin genes have been valuable in assigning
strains to new or known species.
■ MALBRANCHEAMIDES
First identified in 2006 by Mata and co-workers, malbranchea-
mide and malbrancheamide B were isolated from Malbranchea
aurantiaca RRC1813, a fungus obtained from bat guano found
in a cave in Mexico (Table 2).10 Shortly following the isolation
of malbrancheamide and malbrancheamide B, Mata and co-
workers reported the presence of the nonhalogenated precursor
malbrancheamide C, which was later named premalbranchea-
mide.10c This unique family of halogenated secondary
metabolites has expanded recently with the isolation of two
new chlorinated metabolites, (−)-spiromalbramide and (+)-iso-
malbrancheamide B, from Malbranchea graminicola, as reported
by Crews and co-workers.10d Furthermore, two brominated
analogues, (+)-malbrancheamide C (hereafter referred to as
(+)-malbrancheamide “C”) and (+)-isomalbrancheamide C,
were obtained from M. graminicola when the growth medium
was enriched with bromine salts.
This family of natural products represents the only bicyclo-
[2.2.2]diazaoctane-containing metabolites to be reported from
a fungal source outside the genera Penicillium and Aspergillus.
Taxonomically, the strain of M. aurantiaca (RRC1813) may
either be that species or represent the species M. graminicola,
since three strains of M. aurantiaca from the CBS collection
(CBS 127.77, Utah, ex culture contaminant, type strain; CBS
759.74 and CBS 309.76, both ex soil, India) did not produce
Table 1. Culture Collection Strains Producing Secondary Metabolites with a Bicyclo[2.2.2]diazaoctane Unit and Related
Compounds (new data: Frisvad, unpublished)
secondary metabolite fungal species producers: isolates available in international culture collections
malbrancheamides Malbranchea
aurantiacaa
M. graminicola
(RRC1813)b (UCSC 086937A)
chrysogenamide P. chrysogenum (No. 005)b
brevianamides P. viridicatum IMI 039755ii,c IMI 351305, IMI 351306, NRRL 869, NRRL 870, NRRL 959, NRRL 962, NRRL 3586,
NRRL 3600, NRRL A-15402, NRRL A-18563, NRRL A-26909
P. brevicompactum CBS 257.29,c CBS 256.31, CBS 316.59, CBS 317.59, CBS 480.84, CBS 100068, CBS 110069, NRRL 867,
NRRL 32579
A. carlsbadensis CBS 123894c
deoxybrevianamides A. pseudoustus NRRL 5856,c MRC 096
P. italicum ATCC 48952, CBS 339.48, CBS 278.58, CBS 349.75, CBS 489.84,
P. ulaiense CBS 136.41, CBS 210.92, CBS 722.92, CBS 262.94
paraherquamides P. brasilianum CBS 253.55,c CBS 338.59
P. cluniae CBS 276.89c
P. glaucoroseum NRRL 908c
P. cf. canescens ATCC 20841, IMI 332995
paraherquamide E A. aculeatinus CBS 204480
A. f ijiensis CBS 313.89,c IMI 337664a
asperparalines A. aculeatinus ATCC 204480 = JV-23, CBS 101.43, CBS 186.67, CBS 610.78, CBS 621.78, CBS 116.80, CBS 121060,
CBS 121875
A. f ijiensis CBS 313.89,c CBS 119.49, IMI 337664a
notoamides (including
(−)-versicolamide)
A. bridgeri CBS 350.81c
A. melleus CBS 546.65,c NRRL 394
A. ochraceus CBS 108.08,c CBS 589.68, CBS 624.78, NRRL 6319, (CL41582)
A. ostianus CBS 103.07,c CBS 101.23, CBS 311.80, IMI 177964b, IMI 348937, NRRL 422, NRRL 5225, NRRL A-15156,
(01F313)
A. persii CBS 112795c
A. petrakii CBS 105.57c
A. sclerotiorum CBS 549.65,c ATCC 18413, NRRL 5167, (CNC358)
A. westerdijkiae CBS 112803c = NRRL 3174, CBS 112791, CBS 112804, NRRL 5175, NRRL 5221, NRRL 5228,
notoamides (including
(+)-versicolamide)
A. protuberus CBS 602.74,c CBS 601.74
A. versicolor CBS 118.50, CBS 106.57, CBS 599.65, IMI 096225, NRRL 35600
A. elongatus CBS 387.75c
austamide A. pseudoustus NRRL 5856,c MRC 096
citrinadins P. citrinum CBS 139.45,c (N-059)
PF1270 citrinadins P. westlingii (PF1270)
talathermophilins Talaromyces
thermophilus
CBS 116.72, (YM 1−3)
aPossible misidentification. bStrain unavailable. cType strain.
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the malbrancheamides or penicillic acid.10e However, the isola-
tion of (+)-malbrancheamide, (+)-malbrancheamide B,
(+)-premalbrancheamide, and (−)-spiromalbramide from
M. graminicola indicates that these compounds are common
in the genus Malbranchea.
Structurally, the malbrancheamides are the first members of
this class of metabolites to display halogenation of the indole
moiety. While malbrancheamide was determined to contain
chlorination at the C-5 and C-6 position of the indole, the exact
structure of malbrancheamide B was unclear. By synthesizing
both the C-5-chlorinated and C-6-chlorinated potential
compounds, it was established that malbrancheamide B contains
C-6 monochlorination.21 In conjunction with the unique indole
chlorination, the malbrancheamides are also characterized by
the syn-configuration about the bridging bicycle, as well as the
presence of a monoketopiperazine moiety in the core bicycle.
Biologically, the malbrancheamides were determined to display
calmodulin inhibitory activity of CaM-dependent phosphodies-
terase (PDE1).10c,f
Following the isolation of the malbrancheamides, interest
was sparked in elucidating the biosynthetic timing of the indole
chlorination. As shown in Scheme 3, the initially proposed
biogenesis of the malbrancheamides begins with the con-
densation of tryptophan, proline, and dimethylallyl pyrophos-
phate to afford the known natural product deoxybrevianamide E.
From here, two distinct biosynthetic pathways are possible to
form the known metabolite premalbrancheamide. One
potential pathway involves oxidation of deoxybrevianamide E
to yield the Diels−Alder precursor 5-hydroxypyrazin-2(1H)-
one (4a), which would undergo [4+2] cycloaddition to afford
keto-premalbrancheamide. Subsequent carbonyl reduction of
the tertiary amide would provide premalbrancheamide. On
the other hand, carbonyl reduction could occur prior to the
IMDA reaction, in which 4b would serve as the key achiral
intermediate and direct intermediate to premalbrancheamide.
Two individual and concurrent halogenases would then lead
from premalbrancheamide to malbrancheamide B and then to
malbrancheamide.
Table 2. Fungal Origin of the Malbrancheamides
Scheme 3. Proposed Biosynthesis of the Malbrancheamides
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To test whether premalbrancheamide and/or keto-premal-
brancheamide serve as biosynthetic precursors to the
halogenated metabolites, doubly 13C-labeled premalbranchea-
mide and keto-premalbrancheamide were synthesized by
Williams et al. and provided to M. aurantiaca in separate
precursor incorporation studies (Scheme 4).10f Results from
these feeding studies showed significant incorporation of [13C]2-
premalbrancheamide into malbrancheamide B (5.5% incorpo-
ration), but surprisingly, [13C2]-keto-premalbrancheamide did
not incorporate. The latter result suggests that the timing
for the reduction of the tryptophan-derived amide carbonyl
residue must occur prior to the [4+2] cycloaddition; thus the
biosynthetic formation of premalbrancheamide most likely
arises from the proposed intermediate 4b. Future genetic and
biochemical analysis of the malbrancheamide biosynthetic
pathway will undoubtedly resolve the mechanism of mono-
ketopiperizine assembly by M. aurantiaca.1
■ CHRYSOGENAMIDE
In 2008, Zhu and co-workers were interested in identifying
new neuroprotective compounds from endophytic fungi on the
parasitic plant Cistanche deserticola collected in northwest
mainland China (Table 3).9 From the roots of C. deserticola,
three active strains were screened for neuroprotective effects on
SH-SY5Y cells, and the fungal culture Penicillium chrysogenum
No. 005 demonstrated significant activity. From P. chrysogenum,
the novel metabolite chrysogenamide A was isolated. From
a taxonomic perspective, even though the original culture was
not available for examination, other secondary metabolites
characteristic of P. chrysogenum were also isolated,9 supporting
the identity.22−24
From a structural point of view, this novel metabolite is
closely related to the marcfortines (discussed below) in that
chrysogenamide A was found to contain a bicyclo[2.2.2]-
diazaoctane ring system, a spiro-oxindole moiety, and a
pipecolic acid unit with C-17 methylation. Additionally,
chrysogenamide A displays the rare anti-configuration about
the bridging bicycle and an isoprene unit at the C-7 indole
position, as opposed to the more commonly observed dioxepin
and pyran rings. Chrysogenamide A is the first and only
metabolite of these families of natural products to display
neurocyte protection against oxidative stress-induced cell death.9
■ BREVIANAMIDES
Between 1969 and 1972, Birch and co-workers isolated six
novel secondary metabolites, brevianamides A−F (Figure 3),
from Penicillium brevicompactum.3 Of these six metabolites, four
compounds were found to contain the unique bicyclo[2.2.2]-
diazaoctane core. Additional research revealed that breviana-
mides A and B are diastereoisomers, while brevianamides C and
D are artifacts of isolation due to light irradiation.3c Structurally,
the brevianamides were found to display the anti-configuration
about the bicyclic core, as well as the spiro-indoxyl moiety, and
an unsubstituted indole ring. Furthermore, the brevianamides
are a class of natural products that display modest biological
activities, in which brevianamides A and D have been shown to
possess antifeedant and insecticidal effects.25
As shown in Table 4, the brevianamides have been isolated
predominately from two Penicillium species. The two main
producers of brevianamide A are P. brevicompactum3,22,23 and
P. viridicatum,3e,22,23 of which both are consistent producers of
brevianamide A.26 The isolate of P. ochraceum reported to
produce brevianamide A3d was determined to be a brown-
spored mutant of P. viridicatum.26 Deoxybrevianamide E is
produced by P. italicum,27d,e P. ulaiense,22 and a fungus identified
as Aspergillus ustus NRRL 5856.27a−c The latter isolate has been
the basis for the description of a new species, Aspergillus
pseudoustus;28 however, A. pseudoustus is the only species known
to produce austamide (discussed below). The first biosynthetic
Scheme 4. Precursor Incorporation Studies with
M. aurantiaca.
Table 3. Fungal Origin and Bioactivity of Chrysogenamide A
Figure 3. Structures of the brevianamides and related metabolites.
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precursor is the common dioxopiperazine brevianamide F
(cyclo-L-Trp-L-Pro). This alkaloid has been shown to serve as the
precursor for several related secondary metabolites, those
lacking the bridging bicycle, such as the fumitremorgins and
spirotryprostatins in Aspergillus fumigatus.29
Following the isolation of these unique natural products in
1969, which were the first metabolites to be isolated to display
the unusual bicyclo[2.2.2]diazaoctane ring system, Birch and co-
workers carried out several radiolabeled precursor incorporation
studies in order to elucidate early stages of the biosynthetic
pathway of the brevianamides.3a−c,31 Birch demonstrated that
the brevianamides are derived biogenetically from tryptophan,
proline, and mevalonic acid and later showed that radiolabeled
cyclo-L-Trp-L-Pro (brevianamide F) is also a precursor to
brevianamide A in cultures of P. brevicompactum. On the basis
of these results, Birch proposed that brevianamide F arises from
the condensation of tryptophan and proline, which is followed
by C-2 reverse prenylation to afford deoxybrevianamide E.
Oxidation and cyclization of deoxybrevianamide E would give
rise to brevianamides A and B (Scheme 5).
Williams later demonstrated through tracer incorporation
studies with P. brevicompactum that radiolabeled deoxybrevia-
namide E incorporates into brevianamides A, B, and E in
significant radiochemical yields.32 At the same time, Williams
showed that neither tritium-labeled brevianamide E nor the
proposed racemic, 13C-labeled cycloadduct 5 incorporates into
brevianamide A or B when provided to P. brevicompactum in
isotopically labeled precursor incorporation studies (Scheme 6).
These results led to the currently proposed biosynthetic pathway
of brevianamides A and B, as shown in Scheme 6. Since
cycloadduct 5 does not incorporate into the brevianamides, it
was suggested that stereoselective indole oxidation must occur
prior to the formation of the bicyclo[2.2.2]diazaoctane ring
system. Thus, it was proposed that deoxybrevianamide E is first
converted to 3R-hydroxyindolenine (6) via an R-selective indole
oxidase, which could then proceed along one of three pathways.
Following an irreversible nucleophilic addition, 6 could be
readily converted to brevianamide E, or 6 could undergo a
pinacol-type rearrangement to indoxyl 7. A second oxidation−
enolization sequence would then yield the chiral and optically
pure azadiene (3), followed by an IMDA reaction to directly
give brevianamides A and B. It should be noted that efforts to
substantiate this alternative biosynthetic pathway remain elusive
due to complications regarding the synthesis of 7. Despite exten-
sive synthetic efforts, 7 appears to be unstable and spontane-
ously suffers a retro-Michael reaction to give the dehydroalanine
piperazinedione and the reverse-prenylated indoxyl.
Alternatively, reordering these steps would involve the
3R-hydroxyindolenine (6) undergoing two-electron oxidation
and enolization to the corresponding azadiene followed by
intramolecular Diels−Alder cycloaddition and final pinacol-type
rearrangement of the Diels−Alder cycloadducts, each of which
was constituted by a 3R-hydroxyindolenine.
■ MARCFORTINES
In 1980, Polonsky and co-workers reported the isolation of
three new alkaloids from Penicillium roqueforti (later reclassified
as P. paneum), an essential fungus used in the production of
many varieties of blue cheese that contain mold.8a,b From the
strain B26 of P. paneum, marcfortines A, B, and C were isolated
(Figure 4). From a structural point of view, these metabolites
contain the bicyclo[2.2.2] ring system with the syn-config-
uration and a monoketopiperazine ring. Structurally resembling
chrysogenamide A, the marcfortines contain a spiro-oxindole
moiety and an unsubstituted pipecolic acid unit. Furthermore,
all three marcfortine natural products display substitution on
the indole ring at the C-6 and C-7 positions; marcfortines A
and B both contain a dioxepin ring, whereas macfortine C has a
pyran moiety.
As shown in Table 5, the marcfortines were originally
isolated from a strain identified as P. roqueforti;8a,b however, this
species was subsequently subdivided into three distinct species,
P. roqueforti, P. carneum, and P. paneum,33 and it was determined
that only the latter can produce marcfortines.8d,e,22,23 Addition-
ally, Aspergillus carneus has been reported to produce
marcfortine A;4c however, the isolate producing marcfortine A
and acyl aszonalenin differed from the culture ex type of
A. carneus, which produced citrinin. Therefore, the identity of
the marcfortine-producing Aspergillus is questionable.
The biosynthesis of marcfortine A has been investigated by
Kuo et al., and, as shown in Scheme 7, this metabolite is derived
from L-tryptophan (oxindole moiety), L-methionine (via SAM
methylation of the monoketopiperazine N), L-lysine (pipecolate
residue), and acetate (isoprene units).34 On the basis of these
Table 4. Fungal Origin of the Brevianamides
compound fungal species bioactivity reference
brevianamide A P. brevicompactum,
P. viridicatum,
P. ochraceuma
antifeedant
insecticidal
3a−c, e,
d, 25
brevianamide B P. brevicompactum 3a−c
brevianamide C P. brevicompactum 3a−c
brevianamide D P. brevicompactum insecticidal 3a−c, 25
brevianamide Fb A. versicolor,
P. brevicompactum
antibacterial 6f, 3c, 30
brevianamide E P. brevicompactum 3a−c
deoxybrevianamide E Aspergillus sp. MF297-2,c
A. ustus,d P. ulaiense,
P. italicum
6a, 22,
27
aMisidentified fungal culture; correct identification = Penicillium
viridicatum. bWidely distributed biosynthetic precursor; thus only
relevant fungal origins are listed. cUndergoing reidentification (possibly
Aspergillus sclerotiorum). dReclassified as Aspergillus pseudoustus.
Scheme 5. Birch’s Proposed Biosynthesis of the Brevianamides
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results, it is clear that the isoprene residues originate from
mevalonic acid; however, there are two possible biosynthetic
routes for the formation of pipecolic acid from L-lysine, as
shown in Scheme 8.34b To determine which pathway
metabolizes L-lysine to the pipecolic acid unit, Kuo and co-
workers carried out separate feeding studies with [α-15N]- and
[ε-15N]-L-lysine. NMR and MS analysis revealed that the
[α-15N]-L-lysine was incorporated at the α, β, and γ nitrogen of
marcfortine A, with a rate of 1.8%, 13%, and 9%, respectively.
Contrary to this result, [ε-15N]-L-lysine showed an incorpo-
ration rate of 54%, 2.7%, and 3.9% respectively, for the three
Figure 4. The marcfortine family of natural products.
Table 5. Fungal Origin of the Marcfortines
compound fungal species bioactivity references
marcfortine A A. carneus, P. paneum,
P. roquefortia
anthelmintic 8c−e, a, b, f
marcfortine B P. paneum, P. roquefortia 8d, e, a, b
marcfortine C P. paneum, P. roquefortia 8d, e, a, b
aReclassified as Penicillium paneum.
Scheme 7. Biosynthetic Derivatives of Marcfortine A14
Scheme 6. Alternative Biosynthetic Pathway for the Brevianamides
Scheme 8. Two Biogenetic Routes from L-Lysine to
Pipecolic Acid34b
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nitrogens, thus leading to the conclusion that the [ε-15N]-L-
lysine gave a more specific and higher incorporation at the
pipecolate nitrogen. On the basis of these data, pathway A is
the preferred method of L-lysine metabolism to the pipecolic
acid moiety.34b
■ PARAHERQUAMIDES
One of the largest groups of metabolites containing the
bicyclo[2.2.2]diazaoctane ring system is the paraherquamides,
which were first isolated from Penicillium paraherquei,4a a
synonym of P. brasilianum,35 and later from an isolate ATCC
20841, originally identified as P. charlesii.4h However, P. charlesii
was stated incorrectly36 to be a synonym of P. fellutanum by
Pitt,37 and ATCC 20841 has therefore been cited as belonging
to one of these species in later publications. Consequently, this
isolate and another similar isolate producing paraherquamides
(IMI 332995)4e represent a new species closely related to
P. canescens and will be called hereafter P. cf. canescens. Other
producers of paraherquamides include P. cluniae4d and
Aspergillus aculeatinus.4j
Paraherquamide A (Figure 5) was the first member of this
family to be isolated by Yamazaki et al. from P. paraherquei
(= Penicillium brasilianum).4a A decade later, paraherquamide A
was isolated from a fungus identified as P. charlesii (= P.
fellutanum sensu Pitt37) along with six structurally related novel
analogues, paraherquamides B−G.4b,c The original isolate
(ATCC 20841) and a new isolate (IMI 332995) both represent
a new species, provisionally called P. cf. canescens. In the
following years, the paraherquamide family of prenylated indole
alkaloids continued to expand with the isolation of para-
herquamides H and I and several related compounds being
reported, including VM55595, VM55596, VM55597,
VM55599, SB200437, and SB203105.4 More recently, Sherman,
Williams, and co-workers reported the occurrence of pre-
paraherquamide in cultures of the paraherquamide A-producing
P. cf. canescens, as well as in the asperparaline A-producing
fungus Aspergillus japonicus (later identified as A. aculeatinus).4j
Furthermore, it was determined that paraherquamides A and B
are also produced by A. aculeatinus. P. brasilianum, P. cf.
canescens, and P. cluniae, which are all soil fungi and the main
producers of paraherquamides (Table 6).
Structurally, all of the paraherquamides contain the
bicyclo[2.2.2]diazaoctane core with the syn-configuration;
however, the paraherquamide family displays a plethora of
skeletal diversity. For example, the paraherquamides exhibit
varying substitution and oxygenation on not only the proline
ring but also the spiro-oxindole moiety, in that several of the
paraherquamides contain an unusual dioxepin ring, while others
contain a pyran moiety. Within this family of secondary
metabolites, VM55599 and pre-paraherquamide are the only
two compounds that do not contain either a spiro-oxindole
functionality or an oxygenated indole ring system.
The paraherquamides have attracted considerable interest
due to their potent anthelmintic activity. Parasitic nematodes
cause severe health problems in humans and domestic animals,
and the severity of this problem is increasing due to the
development of drug-resistant strains of parasites.38 Initial
anthelmintic activity was detected in Trichostrongylus colubri-
formis,39 and subsequent investigations showed that para-
herquamide A is effective against strains of parasites that are
resistant to broad-spectrum anthelmintics.40 However, the
toxicity of paraherquamide A was determined to be too great
for use as a broad-spectrum anthelmintic.41 To decrease the
toxicity, but still maintain potency, several paraherquamide
derivatives have been synthesized and tested for anthelmintic
activity.38 Of these derivatives, 2-deoxyparaherquamide A
(Figure 6), later named derquantel (Pfizer), displayed excellent
activity in models of Hemonchus contortus, T. colubriformis, and
Ostertagia ostertagi, while maintaining a safe level of toxicity.
Manufacturing of 2-deoxyparaherquamide relies on a semi-
synthetic procedure wherein paraherquamide is isolated from
large-scale fermentation of P. simplicissimum, purified, and
chemically converted to the 2-deoxyparaherquamide ana-
logue.38 This new spiroindole was released in July 2010 as a
combination treatment with abamectin and is currently
marketed under the brand name Startect for use as an
anthelmintic in sheep.42
Elucidating the biosynthesis of paraherquamide A has been an
area of intense research for several years, largely by Williams et al.
Figure 5. Structures of the paraherquamides and related compounds.
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On the basis of the results obtained from the precursor incor-
poration studies of the brevianamides, this group postulated
that the structurally similar paraherquamides follow a com-
parable biosynthetic pathway. To determine which amino acid
residues are incorporated into paraherquamide A, feeding
experiments were performed with P. cf. canescens using [1-13C]-
L-tryptophan, [methyl-13C]-L-methionine, [1-13C]-L-proline,
and [1-13C]-L-isoleucine (Scheme 9).43 Through 13CNMR
spectroscopy and electrospray mass spectrometry, the position
and percentage of 13C incorporation were analyzed, and as
expected, [1-13C]-L-tryptophan incorporated at the C-12
(paraherquamide numbering) position of the oxindole ring
with 2.5% incorporation. Moreover, similar to results obtained
Table 6. Fungal Origin of the Paraherquamides
compound fungal species bioactivity references
paraherquamide A P. charlesii,a P. cluniae, P. brasilianum (= P. paraherquei), Penicillium sp. IMI 332995,a
Penicillium species
anthelmintic
antinematodal
4b−d, a, e, g,
38−42
paraherquamide B P. charlesii,a P. cluniae antinematodal 4b−d
paraherquamide C P. charlesiia antinematodal 4b, c, h
paraherquamide D P. charlesiia antinematodal 4b, c, h
paraherquamide E Aspergillus sp. IMI 337664, A. aculeatus, P. charlesii,a P. cluniae,
Penicillium sp. IMI 332995,a Penicillium species
antinematodal 4f, b, c, h, k, d, e, g
paraherquamide F P. charlesii,a Penicillium sp. IMI 332995, Penicillium species antinematodal 4b, c, h, e, g
paraherquamide G P. charlesii,a Penicillium sp. IMI 332995,a Penicillium species antinematodal 4b, c, h, e, g
paraherquamide H P. cluniae 4d
paraherquamide I P. cluniae 4d
VM55595 Penicillium sp. IMI 332995a 4e
VM55596 P. cluniae insecticidal 4d
VM55597 P. cluniae, Penicillium sp. IMI 332995a insecticidal 4d, e
VM55599 P. paneum, Penicillium sp. IMI 332995,a A. japonicus,b P. charlesiia 4i, k, e, j
SB200437 Aspergillus sp. IMI 337664c anthelmintic 4f
SB203105 Aspergillus sp. IMI 337664c anthelmintic 4f
pre-paraherquamide A. japonicus,b P. charlesiia 4j
aReclassified as a new species related to Penicillium canescens. bReclassified as Aspergillus aculeatinus. cReclassified as Aspergillus f ijiensis.
Figure 6. Structure of 2-deoxyparaherquamide A (derquantel).
Scheme 9. (A) 13C-Labeled Amino Acid Incorporation into Paraherquamide A in Penicillium cf. canescens; (B) Proposed
Biosynthetic Pathway for the Conversion of L-Isoleucine to 3(S)-Methyl-L-proline43
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in the marcfortine biosynthesis, a small amount (0.6%) of
[methyl-13C]-L-methionine was found to incorporate at the
nitrogen methyl of the monoketopiperazine ring.
With regard to the biogenesis of the β-methyl-β-hydroxypro-
line ring, precedent established by Arigoni and co-workers in
the biosynthesis of bottromycin revealed incorporation of
[methyl-13C]-L-methionine into the natural product at the 3(R)-
methyl group of the β-methylproline ring of bottromycin.43b
However, results from the precursor incorporation study with
P. cf. canescens showed that neither [methyl-13C]-L-methionine
nor [1-13C]-L-proline incorporated into the β-methyl-β-
hydroxyproline ring of paraherquamide A. It was later found
that [1-13C]-L-isoleucine exhibited incorporation to the extent
of 3.3−3.7%, with the label at the C-18 position. To establish
a potential mechanism of incorporation of isoleucine into
paraherquamide A, [13C]-[2H]3-L-isoleucine was synthesized
and fed to cultures of P. cf. canescens.43c,d Results showed that
only one deuterium label was retained, thus confirming a
four-electron oxidative cyclization pathway to form β-methyl-L-
proline (Scheme 9B).
This possibility was supported by an additional 13C-labeling
study, which revealed a higher percentage of 13C incorporation
in the monoketopiperazine ring when L-isoleucine underwent
oxidative cyclization to form the β-methyl-L-proline prior to the
precursor incorporation study with P. cf. canescens. An incorpora-
tion of 14.6% was observed in this case, compared to the
previously observed 3.7% incorporation of L-isoleucine.43c,d
Additional biosynthetic research, regarding the exact origin
of the two isoprene units present in paraherquamide A, has
been carried out and rigorously analyzed by Williams and
colleagues. By providing [13C2]-acetate to P. cf. canescens it was
demonstrated that the isoprene units in paraherquamide A were
introduced in two distinct ways (Scheme 10).11,12 Through
13CNMR spectroscopy, the coupling of intact C2 units revealed
that in the C5 fragment formed by C-19 to C-23, C-19 was
coupled to C-20, while C-21 was coupled to C-22 and C-23,
but not to both simultaneously. For the second C5 unit in
paraherquamide A, C-24 to C-28, the coupling constants
showed that C-24 was coupled to C-25, while C-26 was coupled
to C-27, but not to C-28.11,12 On the basis of the observed
coupling patterns, it was concluded that the introduction of the
C-24 to C-28 isoprene unit must proceed through a direct
prenyl transfer in which nucleophilic displacement occurs at the
pyrophosphate-bearing methylene carbon, while the hydro-
phobic tail of DMAPP is buried in the enzyme active site.
The mechanistic formation of the C-19 to C-23 fragment was
further complicated by the observed scrambling of the 13C
labels of the geminal methyl groups at C-22 and C-23, thus
indicating a loss of stereochemical integrity during the
biosynthetic construction of the quaternary center.11,12 These
unexpected results pointed to a non-face-selective reverse
prenyl transferase. In this case, the olefinic π system of DMAPP
is presented in such a manner that both faces are susceptible
to attack by the 2-position of the indole moiety. As shown in
Scheme 11, one possible explanation is that the pyrophosphate
group is anchored in the enzyme active site with the hydro-
phobic isopropenyl moiety being presented in a conformation-
ally flexible disposition (A ⇄ B).
As shown in Scheme 12, the advanced hexacyclic indole
derivative, 13C-labeled pre-paraherquamide, was synthesized
and provided to P. cf. canescens in a precursor incorporation
study.44 Results showed that this material incorporated with the
double label intact and 13C-incorporation of 0.72%, suggesting
that pre-paraherquamide is in fact a pathway metabolite in
paraherquamide biosynthesis. This information also indicates
that formation of the dioxepin ring and the spiro-oxindole
moiety occurs after the formation of this intermediate.
Furthermore, the dioxopiperazine version of pre-paraherqua-
mide (8) was also synthesized as an isotopomer and fed to P. cf.
canescens; however, no incorporation was detected. Therefore,
reduction of the tryptophan-derived carbonyl residue to the
Scheme 10. Relevant Coupling Patterns Observed in the 13C
NMR Spectrum of Paraherquamide Aa
aThick lines represent intact acetate units.12
Scheme 11. Proposed Biosynthetic Mechanism of Reverse Prenylation in Paraherquamide A to Explain the Scrambling of the
Geminal Methyl 13C Labels Observed during the Precursor Incorporation Study12
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monoketopiperazine ring system must occur prior to formation
of the core bridging bicycle.44 These results are also consistent
with the similar observation discussed above, regarding the
biosynthesis of malbrancheamide.
Taken together, the data indicate that the subfamilies of
alkaloids bearing a monoketopiperazine ring system might
derive from a nonribosomal peptide synthase (NRPS) that
reductively cleaves the dipeptide from the thiolation domain,
resulting in off-loading of the tryptophan-derived carboxyl
group as an aldehyde.1 Ring closure of the cyclic amino acid
secondary amine on this aldehyde results in imine formation
followed by tautomerization to an azadiene (see Scheme 3).
The azadiene intermediate then undergoes an IMDA to furnish
the bicyclo[2.2.2]diazaoctane ring system. Conversely, the
subfamilies that are comprised of a dioxopiperazine-based
bicyclo[2.2.2]diazaoctane ring core would arise via an oxidative
process to generate an azadiene species (see Scheme 6).
■ ASPERPARALINES
Asperparaline A is an indole-derived alkaloid containing the
core bridging bicycle that was first isolated in 1997 by Hayashi
and co-workers from the fungus A. japonicus JV-23, in Sakai,
Japan.7a However, the group of uniseriate black Aspergillus
species has been extended from one species to seven species, and
their chemical profiling has shown that the actual asperparaline
producers are A. aculeatinus and A. f ijiensis (Table 7).45,46
In 2000, the same group reported the isolation of two new
related indole alkaloids, asperparalines B and C, from the same
fungal strain.7b In separate work, Everett et al. reported the isola-
tion of asperparaline A, named aspergillimide, from Aspergillus sp.
IMI 337664.7c From the same fungal culture, most likely the new
species A. f ijiensis, the 16-keto derivative of asperparaline A was
isolated and named SB202327. From a structural point of view,
the asperparalines possess the core bicyclo[2.2.2]diazaoctane
ring system. In addition, asperparalines A and B both contain a
β-methylproline ring, whereas asperparaline C is the C-3-
desmethyl analogue. The asperparalines also contain a unique
3-spiro-succinimide ring system, the orientation of which is
consistent with the relative configuration of the spiro-oxindole
ring system present in the paraherquamides.47
All members of the asperparaline family have exhibited
some form of biological activity. Asperparaline A exhibited
paralysis against silkworms at a dose of 10 μg/g of the diet
within 1 h and lasted for 7 to 10 h upon oral administration.7
Asperparalines B and C displayed almost the same effect on
silkworms. Separately, asperparaline A and SB202327 were
tested for anthelmintic activity against adult Trichostrongylus
colubriformis infection in gerbils.7 Results from this experiment
showed that asperparaline A displayed a 44% and 98% reduction
in fecal egg count when dosed at 10 and 20 mg/kg, respectively.
SB202327 exhibited in vitro activity against Hemonchus contortus
L3 larvae, but did not display in vivo activity against
T. colubriformis in gerbils.
Since the asperparaline carbon skeleton closely resembles the
paraherquamides, Williams and co-workers directed their atten-
tion toward elucidating the biosynthesis of the asperparalines.
Scheme 12. Incorporation of 13C-Labeled Pre-paraherquamide into Paraherquamide A in P. cf. canescens
Table 7. Fungal Origin and Bioactivity of the Asperparalines
aReclassified as Aspergillus aculeatinus. bThis strain is probably Aspergillus f ijiensis, which has pink sclerotia like IMI 337664.46f
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To determine the primary amino acid building blocks of as-
perparaline A [1,2-13C2]-acetate, [methyl-
13C]-L-methionine,
[1-13C]-L-isoleucine, [1-13C]-L-tryptophan, and [indole-2-13C]-
L-tryptophan were employed in precursor incorporation studies
(Scheme 13).47 The position of the 13C enrichment in
asperparaline A was determined by 13CNMR, and the
percentage of labeled amino acid enrichment was determined
by 13CNMR and electrospray mass spectrometry. Results
showed that [1,2-13C2]-acetate incorporates into asperparaline
A in an analogous manner to that of paraherquamide A,
indicating that the isoprene units in asperparaline A also arise
from the mevalonic acid pathway. A significant amount of
incorporation from [methyl-13C]-L-methionine was observed at
the C-29 (25.2%) and C-30 (26.9%) positions of asperpara-
line A, but no incorporation was observed in any part of the
β-methylproline ring. However, as expected, [1-13C]-L-isoleucine
exhibited a 5.8% incorporation at the C-18 position of the
β-methylproline ring, which indicates that the β-methylproline ring
in both asperparaline A and paraherquamide A is biosynthe-
sized along a similar, if not identical route. While the
asperparalines appear at first glance to be the only prenylated
indole alkaloids not derived from tryptophan, the precursor
incorporation studies show otherwise. Both [1-13C]-L-tryptophan
and [indole-2-13C]-L-tryptophan showed incorporation at the
C-12 (6.4−7.2%) and C-2 (12.2%) positions of asperparaline A,
respectively. This indicated that tryptophan is responsible for
the construction of the spiro-succinimide ring found in the
asperparalines.
Results from the precursor incorporation studies, along with
the recent detection of pre-paraherquamide in A. aculeatinus,
provide indirect support that (a) pre-paraherquamide is a
precursor to asperparaline A and (b) paraherquamide A and
asperparaline A share a unified biosynthetic scheme.4j To address
both of these hypotheses, a unified biosynthetic pathway has
been proposed. As illustrated in Scheme 14, the proposed unified
biogenesis of paraherquamide A and asperparaline A arises from
pre-paraherquamide, which is derived from the common
precursors L-tryptophan, L-isoleucine, and DMAPP.44,47 From
pre-paraherquamide, the biosynthesis of paraherquamide A could
arise via oxidation of the aromatic ring of pre-paraherquamide to
the catechol derivative (9), followed by prenylation, dioxepin
formation, and oxidation to the spiro-oxindole.12 Along this same
pathway, formation of the spiro-succinimide ring of asperparaline
A would occur via interruption of the paraherquamide A
biosynthesis just before the prenylation step of the catechol
derivative.47 This would provide a possible branching point for
the oxidative cleavage of four carbons of the aromatic ring, thus
resulting in the formation of the spiro-succinimide moiety.
■ STEPHACIDINS AND NOTOAMIDES
The stephacidins and notoamides comprise a family of prenylated
indole alkaloids closely related to the paraherquamides. The first
member to be isolated of what was to become the stephacidin
and notoamide families was sclerotiamide (Figure 7). This was
identified in 1996 from Aspergillus sclerotiorum by Gloer and
White and was actually classified as a paraherquamide-type
compound, despite containing a diketopiperazine as opposed to
a monoketopiperazine, as all paraherquamide family members
are constituted.5a Structurally similar to the paraherquamides,
sclerotiamide contains the core bicyclo[2.2.2]diazaoctane
Scheme 13. Asperparaline A Precursor Incorporation Study
Scheme 14. Proposed Unified Biosynthetic Pathway with Branch Point to Generate Paraherquamides or Asperparalines47
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moiety, a spiro-oxindole ring system with a pyran group, and an
unsubstituted proline ring. However, unlike the paraherqua-
mides, sclerotiamide retains an unreduced dioxopiperazine unit
and also contains a unique C-10 hydroxyl group (para-
herquamide numbering). At the time, the unusual structural
skeleton of sclerotiamide made it appear to be a member of the
paraherquamides.
It was not until 1999 that other structurally related
prenylated indole alkaloids were isolated, including (+)-stepha-
cidin A, stephacidin B, and avrainvillamide.5b,c Stephacidins A
and B were both isolated from the terrestrial-derived Aspergillus
ochraceus WC76466 by a group at Bristol-Myers Squibb,5b,c
while avrainvillamide was isolated independently from a marine-
derived Aspergillus sp. CNC358 by Fenical and associates.5d
Two years later, Sugie and co-workers reported the isolation of
avrainvillamide, under the name of CJ-17,665, from A. ochraceus
CL41582.5e
In 2007, Tsukamoto and co-workers isolated notoamides
A−D (Figure 8) from a marine-derived Aspergillus sp. MF297-2
found growing on the mussel Mytilus edulis, collected off the
Noto Peninsula in the Sea of Japan.6a Along with the
notoamides, the known compounds sclerotiamide, (+)-stepha-
cidin A, and deoxybrevianamide E were also obtained.
Notoamides A−D contain the pyranoindole ring system
common in the stephacidins and some of the para-
herquamides. Notoamides A and B both contain the core
bridging bicycle with C-12 oxidation (paraherquamide
numbering), as well as the spiro-oxindole ring system. In
Figure 7. Structures of the stephacidins and related compounds.
Figure 8. Structures of the notoamides and related compounds.
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2005, a group of structurally similar indole alkaloids, named
the norgeamides, was isolated at the Hans-Knöll Institute from
a cold water Aspergillus sp.48 Minor metabolites of the
notoamides continue to be isolated from marine-derived
Aspergillus sp. MF297-2; notoamides E−R are known natural
products, while notoamides S and T are potential biosynthetic
intermediates that have yet to be isolated.2,6b−e,49
Stephacidin A and notoamide B were also isolated recently
from the terrestrial fungus Aspergillus versicolor, along with a
new metabolite, versicolamide B.6f This new secondary
metabolite displays the rare anti-relative configuration at C-6
(stephacidin numbering) in the bicyclo[2.2.2]diazaoctane ring
system, which is similar to that in brevianamides A and B.
Following the isolation of versicolamide B from A. versicolor, it
was found that this metabolite is also produced by the marine-
derived Aspergillus sp. MF297-2.6d Further investigation of the
metabolites isolated from A. versicolor and Aspergillus sp.
MF297-2 led to the discovery of another unique trait within
this family. (−)-Stephacidin A, (+)-notoamide B, and
(+)-versicolamide B from A. versicolor are the corresponding
enantiomers to (+)-stephacidin A, (−)-notoamide B, and
(−)-versicolamide B produced by the marine-derived Aspergillus
sp. MF297-2 (Figure 9).6f Additionally, (−)-stephacidin A is
the enantiomer of (+)-stephacidin A isolated from A. ochraceus
WC76466, a terrestrial fungus. The discovery of these
enantiomeric metabolites produced by two different Aspergillus
species represents the first known occurrence of reverse
prenylated enantiomeric natural products.
As shown in Table 8, numerous prenylated indole alkaloids
belonging to the stephacidin and notoamide family have been
isolated from various Aspergillus fungal cultures. Taxonomically,
the notoamides (stephacidins, aspergamides, avrainvillamides,
sclerotiamide, versicolamide, norgeamides) are produced by
two groups of Aspergillus: species in sections Circumdati and
Versicolores. In section Circumdati, A. sclerotiorum,5a A.
ochraceus,5b−d A. ostianus,6g and A. westerdijkiae50 can produce
notoamides. In addition, chemical screening has shown that
A. melleus, A. persii, A. petrakii, and A. bridgeri can also produce
notoamides, while the remaining 12 species in section Circumdati
do not appear to produce them. In Aspergillus section Versicolores, a
strain of A. versicolor can produce the stereoisomers, as compared
to those produced by species in section Circumdati of the
notoamides.6f We have detected these compounds later in other
strains of A. versicolor and in two strains of the closely related
species Aspergillus protuberus (Frisvad, Unpublished).
Biologically, the notoamides appear to have moderate and
limited biological activity, while the structurally related norgea-
mides have all been shown to inhibit the growth of a variety of
cancer cell lines with varying efficacies.51 Preliminary biological
assays revealed that norgeamide A is the most cytotoxic against
several carcinoma cell lines. However, sclerotiamide, avrainvilla-
mide, and stephacidins A and B appear to be the most bioactive of
the stephacidins and notoamides. These secondary metabolites
display anti-insecticidal, antibacterial, and cytotoxic properties.5a,c,e
Sclerotiamide has been shown to exhibit potent activity
against first instar larvae of the corn earworm Helicoverpa zea.5a
When incorporated into standard test diets of 200 ppm,
sclerotiamide resulted in a 46% mortality rate of H. zea. There
was also a 98% reduction in growth rate, relative to controls,
Figure 9. Structures of the enantiomeric metabolites produced by
Aspergillus sp. MF297-2 and A. versicolor.
Table 8. Fungal Origin of the Stephacidins and Notoamides
compound fungal species bioactivity reference
sclerotiamide A. sclerotiorum, Aspergillus
sp. MF297-2a
insecticidal
antifeedant
5a, 6a
(+)-stephacidin A A. ochraceus WC76466,
Aspergillus
sp. MF297−2a
cytotoxic 5b, c, 6a
(−)-stephacidin A A. versicolor 6f
stephacidin B A. ochraceus WC76466 cytotoxic 5b, c
avrainvillamide A. ochraceus CL41582,
Aspergillus sp. CNC358
antibiotic
cytotoxic
5e, d
notoamide A Aspergillus sp. MF297−2a 6a
(−)-notoamide B Aspergillus sp. MF297-2a 6a
(+)-notoamide B A. versicolor 6f
notoamide C Aspergillus sp. MF297a 6a
notoamide D Aspergillus sp. MF297a 6a
notoamide E Aspergillus sp. MF297a 6b
notoamide F Aspergillus sp. MF297,a
A. ostianus
6c, g
notoamide G Aspergillus sp. MF297a 6c
notoamide H Aspergillus sp. MF297a 6c
notoamide I Aspergillus sp. MF297a 6c
notoamide J Aspergillus sp. MF297a 6c
notoamide K Aspergillus sp. MF297a 6c
notoamide L Aspergillus sp. MF297a 6d
notoamide M Aspergillus sp. MF297a 6d
notoamide N Aspergillus sp. MF297a 6d
notoamide O Aspergillus sp. MF297a 6e
notoamide P Aspergillus sp. MF297a 6e
notoamide Q Aspergillus sp. MF297a 6e
notoamide R Aspergillus sp. MF297,a
A. ostianus
6e, g
(−)-versicolamide B Aspergillus sp. MF297a 6d
(+)-versicolamide B A. versicolor 6f
norgeamide A Aspergillus species cytotoxic 48, 51
norgeamide B Aspergillus species cytotoxic 48, 51
norgeamide C Aspergillus species cytotoxic 48, 51
norgeamide D Aspergillus species,
A. versicolor
cytotoxic 48, 6f, 51
aUndergoing reidentification.
Journal of Natural Products Review
dx.doi.org/10.1021/np200954v | J. Nat. Prod. 2012, 75, 812−833825
among the survivors. Several physiological effects, such as
shriveling and blackening, were also observed in the larvae. In a
feeding assay against adults and larvae of the fungivorous beetle
Carpophilus hemipterus, at a 100 ppm dietary level, sclerotiamide
reduced feeding rates by 44% and 40%, respectively.
Avrainvillamide is an antibiotic that inhibits the growth of
multi-drug-resistant Staphylococcus aureus, Streptococcus pyo-
genes, and Enterococcus faecalis with MICs of 12.5, 12.5, and
25 μg/mL, respectively.5e When tested against Escherichia coli,
at 100 μg/mL it showed no antibacterial activity. Avrainvilla-
mide also displays cytotoxic activity against a variety of tumor
cell lines, including human colon HCT116 cell lines, melanoma
MALME-3 M cell lines, and two breast cancer cell lines, βT-549
and T-47D.5d
Stephacidins A and B both demonstrate cytotoxicity against
various human tumor cell lines; however, stephacidin B
exhibited more potent and selective antiproliferative activities,
especially for testosterone-dependent LNCaP cells.5b,c The
effects of stephacidins A and B indicate a novel mode of action
since they are not mediated by p53, mdr, or bc12, and they are
not tubulin- or topoisomerase II-mediated. Recent studies
conducted by Myers et al. suggest that the growth-inhibitory
activity of stephacidin B is a result of retrodimerization to form
the monomer avrainvillamide, which may then act as a novel
Michael acceptor via the α,β-unsaturated nitrone group.52
Following the isolation of the first set of enantiomeric reverse
prenylated indole metabolites, attention has been directed
toward elucidating the biosynthesis of the stephacidins and
notoamides. In collaboration with the Sherman laboratory at
the University of Michigan, additional insight into the
biogenesis of the stephacidins and notoamides was obtained
through genome sequencing of Aspergillus sp. MF297-2 and
A. versicolor.1,53 Through data mining and deep annotation, the
stephacidin and notoamide biosynthetic gene clusters have
been identified and characterized. The target gene cluster in
Aspergillus sp. MF297-2 was identified from an open reading
frame (orf) named notE, using the fumitremorgin gene f tmA as
an in silico probe.1,53a Bioinformatics analysis revealed a total
of 18 genes (notA−notR) encompassing ∼44 kb of DNA
(Figure 10), including a bimodular NRPS (NotE) and two
aromatic prenyltransferases, notC and notF. These latter two genes
were functionally expressed in E. coli, with NotC biochemically
characterized as a normal prenyltransferase and NotF determined
to be a reverse prenyltransferase.
On the basis of the above genome sequencing, bioinformatic
mining, and biochemical studies, a comprehensive stephacidin
and notoamide biogenesis was proposed (Scheme 15).
Following the condensation of tryptophan and proline via
NotE to form the common precursor brevianamide F, NotF is
then responsible for the C-2 reverse prenylation of brevianamide
F to give deoxybrevianamide E.1,53 Subsequent oxidation at the
C-6 indole position gives rise to 6-hydroxydeoxybrevianamide E,
which has been confirmed recently to be the NotC substrate.
The reaction of 6-hydroxydeoxybrevianamide E in the presence
of NotC and DMAPP affords 6-hydroxy-7-prenyldeoxybrevia-
namide E, which we have named notoamide S.
It is the oxidation and tautomerization of notoamide S that
we have proposed presently to give rise to the putative achiral
azadiene intermediate, which undergoes an enantiospecific
IMDA reaction in the respective Aspergillus fungal cultures to
provide the proposed metabolite, notoamide T. Oxidative cycliza-
tion of (+)-notoamide T in Aspergillus sp. MF297-2 would afford
(+)-stephacidin A, which, following an oxidation and pinacol-type
rearrangement to the spiro-oxindole, yields (−)-notoamide B.
The enantiomerically opposite IMDA reaction in A. versicolor
Figure 10. Notoamide (not) biosynthetic gene cluster from Aspergillus sp. MF297-2.
Scheme 15. Currently Postulated Biosynthetic Pathway of the Stephacidins and Notoamides in Aspergillus sp. MF297-2 and
A. versicolor
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would yield (−)-notoamide T to then furnish (−)-stephacidin A
and (+)-notoamide B.
Recent precursor incorporation studies carried out by
Williams et al. have provided further validation for the proposed
biogenesis of the stephacidins and notoamides. More specifically,
(±)-[13C]2-stephacidin A was synthesized and provided to the
marine-derived Aspergillus sp. MF297-2 and the terrestrial-
derived A. versicolor (Scheme 16).54 Analysis of the metabolites
revealed enantiospecific incorporation of (+)-stephacidin A
into (−)-notoamide B and (−)-sclerotiamide in Aspergillus sp.
MF297-2, and (−)-stephacidin A into (+)-notoamide B and
(+)-sclerotiamide in A. versicolor. These results indicate the pres-
ence of stereospecific yet complementary face-selective indole
oxidases in the two fungal cultures.
■ RELATED METABOLITES LACKING THE
BICYCLO[2.2.2]DIAZAOCTANE RING SYSTEM
From a structural point of view, the austamides,27 citrinadins,55
and the PF1270 family of metabolites56 appear to be closely
related to the previously discussed indole alkaloids, albeit
lacking the core bicyclo[2.2.2]diazaoctane nucleus. As shown in
Table 9, these related families of metabolites have been isolated
from various Penicillium and Aspergillus species and also display
a plethora of bioactivity. From a taxonomic perspective, the
citrinidins are produced by Penicillium citrinum,55 and the
closely related PF1270 compounds are produced by Penicillium
waksmanii;56 however it is more likely that Penicillium westlingii
produces both families of compounds, as this species is closely
related to P. citrinum.57 P. westlingii was treated as a synonym of
P. waksmanii by Pitt,37 but has later been shown to be a valid
species.35a,57 Talaromyces thermophilus strain YM 1-3 produces
talathermophilins A and B,58 secondary metabolites related to
notoamide E, except that glycine or alanine is replacing proline
and the end products have a double bond conjugating one of the
ketones in the dioxopiperazine to the indole part of the molecule.
We have found that the glycine and alanine notoamide E
analogues (without the extended conjugation) are also formed in
T. thermophilus CBS 116.72, albeit accumulated in much smaller
amounts compared to the end products. T. thermophilus has
recently been shown to be closely related to Thermomyces and
will probably be transferred to that genus.61c,d This means that
no strains of Talaromyces sensu stricto have been reported to
produce compounds with the core bicyclo[2.2.2]diazaoctane
nucleus yet.
Structurally, austamide, 12,13-dihydroaustamide, and 12,13-
dihydro-12-hydroxyaustamide all contain a spiro-indoxyl group
similar to the brevianamides; however, these metabolites also
contain a unique seven-membered spiro-indoxyl ring.27
Another metabolite isolated from A. pseudoustus is deoxy-
austamide, which displays an eight-membered ring between the
indole and dioxopiperazine ring, making it a potential metabolic
precursor to the austamides. Furthermore, deoxybrevianamide E,
the known biosynthetic precursor to the brevianamides,
stephacidins, and notoamides, was also isolated from austamide-
producing A. pseudoustus, thus indicating the possibility of a
shared biogenesis between the brevianamides and austamides.27
Citrinadins A and B were isolated from the fungus
P. citrinum, which was found growing on the red alga Actinotrichia
fragilis.55 These metabolites appear to be structurally related to
the marcfortine and chrysogenamide families of indole
alkaloids, in that the citrinadins also contain a substituted
pipecolate moiety, C-7 indole substitution, and a spiro-oxindole
ring system. While the citrinadins do not contain the core
bridging bicyclo[2.2.2]diazaoctane, Kobayashi and co-workers
proposed that they could biosynthetically arise from a
marcfortine-type skeleton.55b As shown in Figure 11, loss of
the amide carbonyl carbon (C-18) followed by oxidation at
C-15 and C-20 and methylation at C-17 could lead to an
advanced citrinadin metabolite.
The PF1270 family of metabolites was isolated from a soil-
borne fungal culture, P. waksmanii = P. westlingii, in Japan.56
The carbon skeleton of these metabolites is closely related to
the citrinadins, as well as the marcfortine and chrysogenamide
families. Similar to the citrinadins, PF1270A, PF1270B, and
PF1270C contain a substituted pipecolic acid residue, a
C-7-substituted indole ring, and a spiro-oxindole moiety.
Biosynthetically, this family could also arise from a marcfor-
tine-type compound following loss of the amide carbonyl carbon.
Recently, two novel metabolites, talathermophilins A and B,
were isolated from the thermophilic fungus T. thermophilus.58a
These new metabolites have been postulated to serve as potential
precursors to the more advanced metabolites containing the
bridging bicycle. Unlike notoamide B, metabolites tentatively
identified by HPLC-MS as dihydrotalathermophilins A and B
appear to be efficiently converted into the talathermophilins A
Scheme 16. (±)-[13C]2-Stephacidin A Precursor Incorporation Study with Aspergillus versicolor and Aspergillus sp. MF297-2.
54
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and B, which, according to metabolite profiling, appear to be the
end products. Indeed the structures of dihydrotalathermophilins
A and B were recently elucidated58b and named talathermophilins
C and D. There were no indications of other metabolites with a
bicyclo[2.2.2]diazaoctane ring system and/or any of the spiro-
compounds of the notoamide type in T. thermophilus, where
Table 9. Fungal Origin of Several Related Secondary Metabolites
aReclassified as Aspergillus pseudoustus. bProbably Penicillium westlingii, closely related to P. citrinum.
Figure 11. Possible biosynthetic precursor of citrinadins.
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Table 10. Production of Bicyclo[2.2.2]diazaoctane Compounds and Austamides in Different Ecological/Phylogenetic Series of
Aspergillus and Penicillium (Frisvad, unpublished and refs 22−24, 26, 29, 45, 46, 50, based on the methods described in ref 63)
secondary metabolite group section or series species
production of bicyclo[2.2.2]diazaoctane compounds
(and/or austamides)
brevianamides P. series Olsonii P. brevicompactum +
P. astrolabium −
P. bialowiezense −
P. neocrassum −
P. olsonii −
brevianamides P. series Viridicata P. viridicatum +
P. aurantiogriseum −
P. cyclopium −
P. f reii −
P. melanoconidium −
P. neoechinulatum −
P. polonicum −
P. tricolor −
marcfortines P. series Roquefortorum P. paneum +
P. carneum −
P. roqueforti −
P. psychrosexualis −
marcfortines Aspergillus section Flavipedes A carneus +
A niveus −
A flavipes −
chrysogenamides P. series Chrysogena P. chrysogenum +
P. dipodomyis −
P. f lavigenum −
P. nalgiovense −
P. rubens −
paraherquamides P. series Canescentia P. cf. canescens +
P. canescens −
P. yarmokense −
P. janczewskii −
P. jensenii −
P. murcianum −
P. nigricans −
P. radiatolobatum −
paraherquamides P. series Simplicissima P. brasilianum +
P.cluniae +
P. glaucoroseum +
P. janthinellum −
P. piscarium −
P. pulvillorum −
P. simplicissimum −
asperparalines Aspergillus section Nigri series
Aculeati
A. aculeatinus +
A. f ijiensis +
A. aculeatus −
A. indologenus −
A. japonicus −
A. uvarum −
A. violaceofuscus −
notoamides, stephacidins, aspergamides,
avrainvillamides
Aspergillus section Circumdati A. bridgeri +
A. melleus +
A. ochraceus +
A. ostianus +
A. persii +
A. petrakii +
A. sclerotiorum +
A. westerdijkiae +
A. auricomus −
A. cretensis −
A. elegans −
A. f locculosus −
Journal of Natural Products Review
dx.doi.org/10.1021/np200954v | J. Nat. Prod. 2012, 75, 812−833829
glycine or alanine analogues of the proline-derived metabolites
discussed here could theoretically have been secondary
metabolites in this themophilic species.
■ CHEMOTAXONOMIC OVERVIEW
The bioactive prenylated brevianamide F-derived secondary
metabolites, some of which have the unique bicyclo[2.2.2]-
diazaoctane ring system, have mostly been found in Aspergillus
and Penicillium. The bicyclo[2.2.2]diazaoctane ring system
has been found only in fungi that can produce prenylated
tryptophan-proline (or pipecolic acid) dioxopiperazines and
not in any other tryptophan-containing prenylated dioxopiper-
azines, which are also common in Aspergillus and Penicillium.
However, Malbranchea is unrelated phylogenetically to
Penicillium and Aspergillus, and thus the biosynthetic gene
cluster for the bicyclo[2.2.2]diazaoctane ring system com-
pounds could have been horizontally transferred or established
through convergent evolution. Dioxopiperazines may have been
some of the first secondary metabolites to have been produced
by microorganisms during evolution, as they are of widespread
occurrence and very bioactive.59 More elaborate natural
product structures, like those reviewed here, are of restricted
taxonomic distribution. The genera Penicillium and Aspergillus
are closely related, yet both contain species that can produce
optical enantiomers of the same or nearly the same molecule.
For example, the genus Aspergillus can be subdived into three
major clades,60 all of which contain producers of brevianamide
F. In the Neosartorya clade, the end products based on
brevianamide F (tryptophanyl-prolyl-dioxopiperazine) are the
fumitremorgins and spirotryprostatins;29 in the Emericella clade,
A. versicolor produces (+)-versicolamide B; and, in the Eurotium
clade, A. sclerotiorum produces (−)-versicolamide B. Penicillium
can be roughly subdivided into six clades,61a or 25 clades61b,c
of which only two contain producers of the bicyclo[2.2.2]-
diazaoctane ring system secondary metabolites. Clade 5
contains P. brasilianum, P. glaucoroseum, and P. cluniae, all
producing paraherquamides, while clade 6 contains all the
remaining producers in Penicillium: P. paneum of marcfortines,
P. chrysogenum of chrysogenamides, P. brevicompactum and P.
viridicatum of brevianamides, and the less related P. cf. canescens
of paraherquamides. The food-borne species in Penicillium
subgenus Penicillium appear to represent a hot-spot for
producers of the bicyclo[2.2.2]diazaoctane ring system
compounds, but even within this subgenus, the compounds
are widely distributed among the subclades, even as both anti
(P. chrysogenum) and syn (the other species) compounds. The
production of paraherquamides by soil-borne types of Penicillium
in both clade 5 (P. brasilianum) and 6 (P. cf. canescens) could
Table 10. continued
secondary metabolite group section or series species
production of bicyclo[2.2.2]diazaoctane compounds
(and/or austamides)
A. insulicola −
A. muricatus −
A. neobridgeri −
A. ochraceopetaliformis −
A. pseudoelegans −
A. roseoglobulosus −
A. steynii −
A. sulphureus −
notoamides, opposite stereochemistry Aspergillus series Versicolores A. versicolor +
A. protuberus +
A. sydowii −
austamides and deoxybrevianamides Aspergillus section Usti A. pseudoustus +
A. amylovorus −
A. calidoustus −
A. californicus −
A. carlsbadensis (brevianamide A)
A. cavernicola −
A. def lectus −
A. egyptiacus −
A. elongatus (possibly notoamide E)
A. germanicus −
A. granulosus −
A. heterothallicus −
A. insuetus −
A. kassunensis −
A. keveii −
A. lucknowensis −
A. monodii −
A. pseudodef lectus −
A. puniceus −
A. subsessilis −
A. turkensis −
A. ustus −
deoxybrevianamides P. series Italica P. italicum +
P. ulaiense +
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indicate horizontal transfer of the whole biosynthetic gene cluster
or reinventive evolution guided by selection. Thus, dioxopiper-
azines may have been vertically inherited from a common ancestor
and may be also simple dioxopiperazine prenylation, but the end
products of the biosynthetic routes appear to be unique and
specific for the different species. Within closely related species
the same secondary metabolites seem to be produced and could
thus be derived from a common ancestor. For example, in
Aspergillus section Circumdati, of the 20 different species
known,50 eight produce notoamides and 12 do not, but those
that are produced are of the same chemical type. In section
Circumdati, the notoamides are produced in two different
clades, which are not sister clades.50 The “central” clade contains
A. ochraceus, A. petrakii, A. ostianus, A. melleus, and A. westerdijkiae,50
all producing notoamides, while in a second clade consisting of
A. sclerotiorum, A. persii, A. bridgeri, and A. sulphureus, the three first
species produce notoamides.
In most other clades in Penicillium and Aspergillus one, or
rarely two, out of all species in a series produces bicyclo[2.2.2]-
diazaoctane compounds (Table 10). Thus, metabolites con-
taining the dioxopiperazine and prenylation are very wide-
spread in Aspergillus and Penicillium, but the more complicated
metabolites containing the bicyclo[2.2.2]diazaoctane ring
system are present only in a few species. While it is only P.
paneum that can produce marcfortines in Penicillium series
Roqueforti, all species in the series can produce roquefortine C,
another prenylated diketopiparazine (Trp + His). In the eight
species in Penicillium series Viridicata it is only P. viridicatum
that can produce brevianamide A, but all eight species produce
other prenylated dioxopiperazines:22,23 P. neoechinulatum,
P. aurantiogriseum, and P. f reii produce aurantiamine (Val +
His), P. viridicatum produces the closely related viridamine (Val +
His), P. melanoconidium produces roquefortines (Trp + His), and
P. cyclopium, P. polonicum, and P. tricolor produce verruco-
fortines (Trp + Leu) and puberulines (Trp + Phe). In the five
species in Penicillium series Chrysogena it is only P. chrysogenum
that can produce chrysogenamide, but all species produce either
prenylated dioxopiperazines or unprenylated dioxopiperazines:
P. chrysogenum, P. rubens, and P. f lavigenum produce roquefortine
C (Trp + His), P. dipodomyis and P. nalgiovense produce
dipodazin (Trp + Gly, unprenylated), and P. chrysogenum
produces chrysogenazine (Trp + Ala, prenylated).62 The fact
that prenylated dioxopiperazines are widespread in Penicillium
and Aspergillus, and also occur outside these two genera, and the
fact that the bicyclo[2.2.2]diazaoctane ring system-containing
secondary metabolites are more restricted in their distribution
suggest that these latter natural products are advanced molecules
that appeared later during evolution than other dioxopiperazines.
■ CONCLUSION
Natural products containing the unique bicyclo[2.2.2]-
diazaoctane ring system are intriguing from a synthetic,
biosynthetic, evolutionary, and medicinal perspective. This
unusual ring system is proposed to arise biosynthetically via an
azadiene-mediated intramolecular hetero-Diels−Alder reaction
that has been supported through biomimetic syntheses. An
emerging body of evidence suggests that there are two distinct
biogenetic familes: (1) those constituted of a dioxopiperazine
as an integral part of the bicyclo[2.2.2]diazaoctane ring sys-
tem and (2) those comprised of a monooxopiperazine as an
integral part of the bicyclo[2.2.2]diazaoctane ring system.
Precursor incorporation experiments and recent genetic,
bioinformatic, and biochemical analyses further suggest that
the dioxopiperazine-containing family members, such as stepha-
cidins, arise by oxidative processing of C-2 reverse-prenylated
indole dipeptides that culminate in azadiene formation and
intramolecular Diels−Alder cyclization. Similarly, precursor
incorporation experiments and recent analysis of the NRPS
domains corresponding to the monooxopiperazine-containing
family members indicate that natural products in the larger
paraherquamide family arise by reductive processing of the
initial indole dipeptides, to form a reduced azadiene species,
which undergoes C-2 reverse prenylation and an intramolecular
Diels−Alder cyclization. Whether or not the putative Diels−
Alderases are none other than the oxidase and reductase domains
of the NRPS modules that process the dipeptide intermediates at
an early stage remains to be ascertained. At the heart of this
central question is whether these redox functions catalyze the
IMDA reaction through a pericyclic transition state, or whether
the IMDA reaction is an “afterthought” or spontaneous
construction immediately following the generation of the
respective azadiene species that have been implicated. One of
the most provocative findings in this context has been the
discovery of the enantiomeric natural products stephacidin A,
notoamide B, and versicolamide B, as discussed above, as well as
the production of the diastereomeric and pseudoenantiomeric
substances VM55599 and pre-paraherquamide. These intriguing
stereochemical puzzles remain to be solved and are the subject of
central focus in our laboratories.
The fungal origin of secondary metabolites containing the
bicyclo[2.2.2] nucleus is largely limited to species within the
Aspergillus and Penicillium genera. Moreover, secondary
metabolites with the bicyclo[2.2.2] nucleus appear to be
different from the more widespread prenylated dioxopiperazines
in that they have evolved later and followed recent speciation in
Aspergillus and Penicillium. Comparison of the malbrancheamide
biosynthetic genes in Malbranchea with the parallel ones in
Penicillium and Aspergillus may help clarify whether secondary
metabolite gene clusters are acquired vertically or horizontally or
if they have developed independently during evolution. It is
tempting to ponder if the putative Diels−Alderase genes have
evolved at a different rate than the amino acid cyclases and
prenyl transferases in the producing organisms, a hypothesis that
can be tested using bioinformatics combined with taxonomy and
organic chemistry. The key step that culminates in the formation
of the bicyclo[2.2.2]diazaoctane ring system is also the stage
at which the structural complexity of the simple prenylated
dipeptide progenitors are vastly increased. That Nature has
apparently evolved two distinct mechanistic manifolds (reduc-
tive and oxidative) to build this ring system was an unexpected
yet wonderous discovery that was only made possible through
the synthesis of isotopically labeled biosynthetic intermediates,
whole genome sequencing, and bioinformatic analyses of the
respective gene clusters. The modern tools of whole genome
sequencing, proteomics, bioinformatics, and functional expres-
sion of the biosynthetic genes are currently being deployed to
gain a detailed understanding of the elusive mysteries of the
biogenesis of these structurally complex secondary metabolites.
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